Ahaan Healthcare Private Limited

Ahaan Healthcare Private Limited (AHPL) is a privately held pharmaceutical company incorporated on November 1, 2007, in Satara, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U15139PN2007PTC130947. AHPL specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's authorized share capital is ₹1,000,000, with a paid-up capital of ₹100,000. As of the latest available data, AHPL is led by directors Yatin Narayandas Doshi, Supriya Yatin Doshi, and Mohini Narayandas Doshi.

The company's registered office is located at C/o Mr. Yatin Doshi, 1, Tulsi Vihar, Visawa Park, Satara, Maharashtra, 415001, India. AHPL's website, www.ahpl.co, provides further information about its products and services. The company has been operational for over 18 years, focusing on the production and export of pharmaceutical formulations across various therapeutic categories.

AHPL operates a state-of-the-art manufacturing facility in Satara, Maharashtra, designed to meet WHO Good Manufacturing Practice (GMP) standards. The plant is equipped with ultramodern equipment and machinery, enabling the production of a wide range of dosage forms, including tablets, hard and soft gelatin capsules, dry and liquid syrups, dry and liquid injectables, prefilled syringes, large volume parenterals, eye and ear drops, as well as herbal, nutraceutical, dermatological, hormonal, and cosmeceutical products. (ahpl.co)

The leadership team at AHPL comprises directors Yatin Narayandas Doshi, Supriya Yatin Doshi, and Mohini Narayandas Doshi. Yatin Narayandas Doshi has been serving as a director since November 1, 2007, while Supriya Yatin Doshi joined the board on June 7, 2010, and Mohini Narayandas Doshi on January 1, 2014. Specific roles and responsibilities within the company are not detailed in the available sources.

AHPL's export portfolio includes finished pharmaceutical formulations across three therapeutic categories: gastrointestinal (73.8%), respiratory & OTC (22.6%), and lipid & metabolism (3.6%). The company's top three products are Domperidone ($311K, Rank #14, 1.0% market share), Terbutaline ($95K, Rank #5, 2.7% market share), and Niacin ($15K, Rank #11, 0.4% market share). These figures indicate a focus on gastrointestinal and respiratory treatments, with a significant presence in the respiratory & OTC segment.

AHPL's export data does not specify its presence in emerging markets such as Africa, Latin America, or Southeast Asia. The company's export strategy appears to be concentrated in markets where its top products have established demand, particularly in the gastrointestinal and respiratory therapeutic areas.

The company's export strategy is concentrated on a select range of products, with the top three products accounting for 100% of the export value. This indicates a high level of portfolio concentration, which may expose AHPL to risks associated with market fluctuations in these specific therapeutic areas. Diversifying the product portfolio and exploring new geographic markets could mitigate such risks and enhance the company's market resilience.

Specific details regarding AHPL's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not available in the provided sources. Given the company's focus on finished pharmaceutical formulations, obtaining FDA approvals would be essential for accessing the U.S. market. It is recommended to verify the current status of these regulatory approvals directly with the FDA or through AHPL's official communications.

AHPL's manufacturing facility is WHO GMP certified, ensuring compliance with international quality standards for pharmaceutical manufacturing. However, specific details regarding EU GMP certification or EDQM status are not available in the provided sources. Securing EU GMP certification would be crucial for market access within the European Union.

AHPL holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company's manufacturing facility is located in Satara, Maharashtra, and is subject to inspections and approvals by the state drug controller. Specific details regarding export No Objection Certificates (NOCs) are not available in the provided sources.

There are no publicly available records of Form 483 observations, warning letters, or import alerts issued to AHPL. This suggests a clean regulatory history, which is favorable for the company's reputation and operations.

In the gastrointestinal and respiratory therapeutic segments, AHPL faces competition from both domestic and international pharmaceutical companies. While specific market share data for competitors is not available, the company's focus on a limited product portfolio may position it as a niche player in these segments. Expanding the product range and enhancing market presence could improve competitiveness.

AHPL's key differentiators include its WHO GMP certified manufacturing facility, which ensures adherence to international quality standards, and its specialization in a select range of therapeutic categories, particularly gastrointestinal and respiratory treatments. These strengths enable the company to offer high-quality products tailored to specific market needs.

AHPL's current strategic direction appears to be focused on the production and export of generic pharmaceutical formulations in the gastrointestinal and respiratory segments. The company's future outlook would benefit from diversifying its product portfolio, exploring new therapeutic areas, and expanding into emerging markets to enhance growth and reduce dependency on a limited product range.

AHPL's track record in manufacturing and exporting pharmaceutical formulations is supported by its WHO GMP certification, indicating a commitment to quality and reliability. The company's export volume and consistency are not detailed in the available sources, but the focus on a select range of products suggests a strategic approach to market penetration. Reliability indicators such as on-time delivery and adherence to quality standards are not specified but can be inferred from the company's certifications and product offerings.

Importers should verify the following certifications when considering AHPL as a supplier:

• FDA Approval: To ensure compliance with U.S. regulatory standards for pharmaceutical products. Verification can be done through the FDA's official website or by contacting AHPL directly.

• WHO GMP Certification: To confirm adherence to international manufacturing standards. This can be verified through the World Health Organization's official channels.

• EU GMP Certification: For market access within the European Union. Verification can be conducted through the European Medicines Agency (EMA) or by contacting AHPL.

• ISO Certifications: To assess the company's quality management systems. These can be verified through the International Organization for Standardization (ISO) or by requesting certification details from AHPL.

When conducting due diligence on AHPL, consider the following steps:

• Verify Regulatory Approvals: Confirm FDA, WHO GMP, EU GMP, and ISO certifications through the respective regulatory bodies or AHPL's official communications.

• Assess Financial Health: Review the company's financial statements for the latest fiscal year to evaluate revenue trends, profitability, and financial stability.

• Evaluate Product Portfolio: Analyze the range of products offered, focusing on therapeutic categories, market demand, and competitive positioning.

• Inspect Manufacturing Facilities: If possible, conduct a site visit to assess the manufacturing facility's compliance with quality standards and operational capabilities.

• Review Supply Chain Practices: Assess the reliability and efficiency of AHPL's supply chain, including sourcing of raw materials, production processes, and distribution channels.

• Check for Regulatory Compliance: Ensure the company has a clean regulatory history with no outstanding violations or pending actions.

• Assess Market Reputation: Seek feedback from existing clients, partners, and industry peers regarding AHPL's reputation for quality, reliability, and customer service.

By following this checklist, importers can make informed decisions regarding potential partnerships with AHPL.